Kairos Pharma KAPA
NYSE KAPA
$0.55 +0.01 (+1.05%)
As of: Oct 23, 2026 · 3:59 PM EDT

Kairos Pharma (KAPA) Other Accumulated Expenses (2023)

Updated

Kairos Pharma (KAPA) recorded Other Accumulated Expenses of $4,000 in Q4 2023.

Analysis

Kairos Pharma (KAPA) Other Accumulated Expenses (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Kairos Pharma 10.50 Mn -1.91 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 4,000.00
API Access

Kairos Pharma Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=KAPA&period=max&api_key=YOUR_API_KEY